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Methods 
 
Roswell Park Memorial Institute (RPMI-1640) medium, as well as foetal 
bovine serum, L-glutamine, penicillin/streptomycin mixture, trypsin, 
trypsin/EDTA, phosphate buffered saline (PBS) were purchased from PAA 
Laboratories GmbH. HPLC grade ethanol, β-mercaptoethanol, PI (>94%), 
Annexin V-FITC Apoptosis Detection Kit and RNAse A were obtained from 
Sigma Aldrich. For RNA sequencing, cell shredders and mini-prep kits were 
purchased from Qiagen. 
 
Cell maintenance 
The A2780, human ovarian carcinoma cell line was obtained from the 
European Collection of Cell Cultures (ECACC). Cells were grown in RPMI-
1640 medium supplemented with 10% (v/v) foetal calf serum, 1% (v/v) 2 mM 
glutamine and 1% (v/v) penicillin (10 k units/mL)/streptomycin (10 mg/mL). All 
cells were maintained in 75 mL culture flasks at 310 K with 5% CO2 
humidified atmosphere. Cells were grown as adherent monolayers and split 
when 80-90% confluent, using 0.25% trypsin. 
 
Screening in the Sanger cell panel 
Briefly, cells were seeded in 96 well plates at ca.15% confluency and left to 
incubate for 24 h at 310 K, 5% CO2, 95% air and 100% relative humidity. For 
adherent cell lines, cells were treated with nine concentrations of each 
compound (2-fold dilution series over 256-fold concentration range) and 
returned to the incubator for 72 h. Cells were then fixed with 4% formaldehyde 
for 30 min and stained with 1 μM Syto60 for 1 h. Quantitation of fluorescent 
signal intensity was performed using a plate reader at excitation/emission 
wavelengths of 630/695 nm. For suspension cell lines, cells were treated with 
compound immediately following plating, and returned to the incubator for 72 
h. Cells were stained with 55 μg/mL Resazurin, prepared in glutathione-free 
medium, for 4 h. Quantitation of fluorescent signal intensity was performed 
using a plate reader at excitation/emission wavelengths of 535/595 nm. 
MANOVA analysis was performed by the Sanger Bioinformatics Institute. All 
Figures presented here were reconstructed using the R statistical programme. 
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RNA sequencing 
Experimental  
A2780 cells were seeded in P100 Petri dishes at 3 x 106 cells per plate in 10 
mL RPMI-1640 medium. Plates were incubated for 24 h at 310 K, 5% CO2, 
95% air and 100% relative humidity. Stock solutions of each compound and of 
the vehicle control were prepared in 5% (v/v) DMSO, 10% (v/v) saline, and 
85% (v/v) RPMI-1640 medium. Cells were exposed to complex 2 at a final 
concentration of 400 nM. The final DMSO concentration for all cell samples 
did not exceed 0.05% v/v. After compound addition, cells were incubated for a 
further 4, 12, 24 and 48 h. Medium was aspirated from cells and cells were 
washed twice with PBS before trypsinising and collection. To each sample, 
600 μL RLT lysis buffer (Qiagen) was added and the samples vortexed. 
Lysate was pipetted directly into QIAshredder spin columns (Qiagen) and 
centrifuged. Lysate was transfered to gDNA eliminator spin columns (RNeasy 
plus mini kit, Qiagen) and centrifuged. Columns were discarded and 600 uL of 
70% ethanol was added to each sample flow-through. Samples were 
transfered into RNeasy spin columns (RNeasy plus mini kit, Qiagen) and 
centrifuged. Column-bound RNA samples were washed with RW1 and RPE 
buffer (RNeasy plus mini kit, Qiagen) before RNA collection in 70 μL RNAse-
free water. Samples were stored at 193 K for no more than 2 months. 
Samples were diluted 1:10 fold in RNAse-free water and run on a NanoDrop 
1000 spectrophotometer machine and the absorbance at 230, 260 and 280 
nm recorded to calculate the 260/230 and 260/280 ratios. Samples with 
A260/230 >2.0 and A260/280 >1.9 were passed. The concentration of RNA in 
each solution was also estimated using the NanoDrop and was verified using 
a 2100 Agilent Bioanalyzer and an RNA 6000 Nano Kit (Agilent), and the 
Qubit assay (Life Technologies). All samples had a RNA integrity number 
(RIN) > 9.50. A minimum of 1 μg RNA for each sample was transferred to 
Oxford Genomics Centre (Wellcome Trust Centre for Human Genetics) in a 
total of 30 μL RNAse-free water in skirted 96 well plates. 
 
Reverse phase protein microarrays (RRPA) 
4 x 105 A2780 cells were seeded per well in 6-well plates, with samples in 
duplicate. Cells were pre-incubated in drug-free media for 48 h at 310 K in a 
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5% CO2 humidified atmosphere. After this, cells were treated at 150 nM and 
450 nM of complex 2 for 4, 24, 48 and 72 h. Control samples were treated 
with medium containing 0.1% DMSO. Following exposure, drug-containing 
medium was removed, and cells were washed twice with PBS and lysed with 
CLB1 buffer (Zeptosens-Bayer) according to manufacturer’s instructions. Cell 
lysates were normalised to a uniform protein concentration of 2 mg/mL with 
CLB1 buffer (Zeptosens-Bayer) prior to preparing a final 4-fold concentration 
series of; 0.2; 0.15; 0.1 and 0.75 mg/mL in spotting buffer CSBL1 (Zeptosens-
Bayer). The diluted concentration series of each sample was printed onto 
hydrophobic Zeptosens protein microarray chips (ZeptoChipTM, Zeptosens-
Bayer) under environmentally controlled conditions (constant 50% humidity at 
287 K) using a non-contact printer (Nanoplotter 2.1e, GeSiM). A single 400 pL 
droplet of each lysate concentration was deposited onto the Zeptosens chip. 
A reference grid of Alexa Fluor 647 conjugated BSA was spotted onto each 
sub-array, each sample concentration series was spotted in between 
reference columns. After array printing, the arrays were blocked with an 
aerosol of BSA solution using a custom designed nebuliser device 
(ZeptoFOGTM, Zeptosen-Bayer) for 1.5 h to prevent non-specific antibody 
binding. The protein array chips were subsequently washed in double 
deionised water (DDW) and dried prior to performing a dual antibody 
immunoassay comprising of a 24 h incubation of primary antibodies followed 
by 2.5 h incubation with secondary Alexa Fluor 647 conjugated antibody 
detection reagent (anti-rabbit or anti-mouse 647 Fab, Invitrogen). Following 
secondary antibody incubation and a final wash step in BSA solution, the 
immunostained arrays were imaged using the ZeptoREADER instrument 
(Zeptosens-Bayer). For each-sub-array, five separate images were acquired 
using different exposure times ranging from 0.5-10 s. Microarray images 
representing the longest exposure without saturation of fluorescent signal 
detection were automatically selected for analysis using the ZeptoViewTM 3.1 
software. A weighted linear fit through the 4-fold concentration series was 
used to calculate the relative fluorescence intensity (RFI) value for each 
sample replicate. Local normalisation of sample signal to the reference BSA 
grid was used to compensate for any intra- or inter-array/chip variation. RFI 
values were further normalised to a house keeping protein and to the negative 
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control, to provide the final RFI to represent the relative abundance of total, 
phosphorylated and cleaved proteins in compound-treated samples relative to 
the DMSO control for each time point. 
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Table S1. Summary statistics for RNA sequencing experiment.  
Description Yield Mb Q20 % Mapped 
Avg. Quality 
score 
4 h control 975.855 98.45 36.7 
4 h control 901.135 98.6 36.65 
4 h control 701.445 98.9 36.8 
4 h drug 1016.67 99.1 36.7 
4 h drug 640.475 98.75 36.85 
4 h drug 901.065 98.1 36.65 
12 h control 968.815 98.65 36.65 
12 h control 1208.1 97 36.25 
12 h control 658.935 98.75 37.25 
12 h drug 710.245 97.8 37.1 
12 h drug 651.6 98.75 37.3 
12 h drug 728.13 98.9 37.2 
24 h control 591.46 98.9 37.3 
24 h control 763.42 98.25 37.2 
24 h control 663.875 98.6 37.2 
24 h drug 794.815 98.2 37.2 
24 h drug 754.52 98.65 36.95 
24 h drug 864.57 97.5 36.85 
48 h control 876.415 98.15 36.95 
48 h control 1003.08 97.95 37 
48 h control 853.78 98.25 37 
48 h drug 894.37 95.55 36.8 
48 h drug 811.94 97.3 36.9 
48 h drug 1026.57 97.6 36.8 
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Table S2. Pathway analysis showing the top five most-mapped processes for DEGs 
with -1.0 < LogFC > 1.0 and FDR < 0.05 after exposure to 2. IPA has identified 
pathways of interest, with associated significance p- and z-values.  
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Table S3. Generation of total ROS and superoxide by complex 2 in A2780 ovarian 
carcinoma cells exposed to IC50 concentrations. Values obtained from triplicate 
experiments. Determination of statistical significance by two-sample independent 
Welch t-test assuming unequal variance: p ≤ 0.05 *, p ≤ 0.01 **, p ≤ 0.001 ***, p ≤ 
0.0001 ****. 
 
 
 
High 
Superoxide 
High ROS 
and 
Superoxide 
High ROS 
Low ROS 
and 
Superoxide 
 
FL1-FL2+ FL1+FL2+ FL1+FL2- FL1-FL2- 
  Q1 Q2 Q3 Q4 
Neg CTL 0.17 ± 0.07 0 0 99.82 ± 0.07 
Complex 2 0.1 ± 0.1 84 ± 1 **** 16 ± 1 **** 0.3 ± 0.5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
S9 
 
Table S4. List of publicly-released compounds tested by the Sanger Institute in the 
cell line screen 
 
681640 
(5Z)-7-Oxozeaenol 
17-AAG 
A-443654 
A-770041 
ABT-263 
ABT-869 
ABT-888 
AC220 
AG-014699 
AICAR 
AKT inhibitor VIII 
AMG-706 
AP-24534 
AR-42 
AS601245 
AS605240/KIN001-173 
AT-7519 
ATRA 
AUY922 
AV-951 
AX11492 
Axitinib 
AZ628 
AZD-0530 
AZD-2281 
AZD2281 
AZD6244 
AZD6244 
AZD6482 
AZD6482 
AZD7762 
AZD8055 
BAY 61-3606 
Bexarotene 
BI-2536 
BIBW2992 
Bicalutamide 
BIRB 0796 
BIX02189 
Bleomycin 
BMN-673 
BMS-345541 
BMS-509744 
BMS-536924 
BMS-708163 
BMS-754807 
Bortezomib 
Bosutinib 
Bryostatin 1 
BX-795 
CAL-101 
Camptothecin 
CAY10603 
CCT007093 
CCT018159 
CEP-701 
Cetuximab 
CGP-082996 
CGP-60474 
CH5424802 
CHIR-99021 
CHIR-99021 
CI-1040 
Cisplatin 
CMK 
CP466722 
CP724714 
CUDC-101 
CX-5461 
Cyclopamine 
Cytarabine 
Dasatinib 
DMOG 
Docetaxel 
Doxorubicin 
EHT 1864 
EKB-569 
Elesclomol 
Embelin 
Epothilone B 
Erlotinib 
Etoposide 
EX-527 
FH535 
FK866 
FR-180204 
FTI-277 
GDC-0449 
GDC0941 
GDC0941 
Gefitinib 
Gemcitabine 
Genentech Cpd 10 
GNF-2 
GSK-1904529A 
GSK-650394 
GSK1070916 
GSK1120212 
GSK2118436 
GSK2126458 
GSK269962A 
GSK429286A 
GSK690693 
GW 441756 
GW843682X 
HG-5-113-01 
HG-5-88-01 
HG-6-64-1 (KIN001-
206) 
I-BET 
Imatinib 
INCB-18424 
IPA-3 
JNJ-26854165 
JNK Inhibitor VIII 
JNK-9L 
JQ1 
JQ12 
JW-7-24-1 
JW-7-52-1 
KIN001-055 
KIN001-102 
KIN001-135 
KIN001-167/ZSTK474 
KIN001-175/BX-912 
KIN001-201/TAK-715 
KIN001-236 
KIN001-242/FMK 
KIN001-244 
KIN001-260 
KIN001-266 
KIN001-270 
KU-55933 
Lapatinib 
LAQ824 
Lenalidomide 
LFM-A13 
LY317615 
Masitinib 
Methotrexate 
MG-132 
Midostaurin 
Mitomycin C 
MK-2206 
MLN4924 
MP470 
MPS-1-IN-1 
MS-275 
NG-25 
Nilotinib 
NPK76-II-72-1 
NSC-207895 
NSC-87877 
NU-7441 
Nutlin-3a 
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NVP-BEZ235 
NVP-BHG712 
NVP-TAE684 
Obatoclax Mesylate 
OSI-027 
OSI-906 
OSI-930 
OSU-03012 
PAC-1 
Paclitaxel 
Parthenolide 
Pazopanib 
PD-0325901 
PD-0332991 
PD-173074 
PF-02341066 
PF-4708671 
PF-562271 
PHA-665752 
PHA-793887 
PI-103 
PIK-93 
piperlongumine 
PLX4720 
PLX4720 (for rescreen 
control) 
"PXD101, Belinostat" 
Pyrimethamine 
QL-VIII-58 
QL-X-138 
QL-XI-92 
QL-XII-47 
QL-XII-61 
QS11 
Rapamycin 
RDEA119 
RDEA119 
RO-3306 
Roscovitine 
rTRAIL 
S-Trityl-L-cysteine 
Salubrinal 
SB 216763 
SB-505124 
SB-715992 
SB52334 
SB590885 
Shikonin 
SL 0101-1 
SN-38 
SNX-2112 
Sorafenib 
STF-62247 
Sunitinib 
T0901317 
Tamoxifen 
Temozolomide 
Temsirolimus 
TG101348 
TGX221 
Thapsigargin 
THZ-2-102-1 
THZ-2-49 
Tipifarnib 
TL-1-85 
TL-2-105 
TPCA-1 
Tubastatin A 
TW 37 
UNC0638 
UNC0638 
Vinblastine 
Vinorelbine 
VNLG/124 
Vorinostat 
VX-11e 
VX-680 
VX-702 
WH-4-023 
WZ-1-84 
WZ3105 
XAV 939 
XL-184 
XL-880 
XMD11-85h 
XMD13-2 
XMD14-99 
XMD15-27 
XMD8-85 
XMD8-92 
Y-39983 
YK 4-279 
YM155 
YM201636 
Z-LLNle-CHO 
ZG-10 
"Zibotentan, ZD4054" 
ZM-447439
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Figure S1. Box and whisker plot showing the distribution of log IC50 values for 
complexes 1 (ZL49) (blue), 2 (ZL109) (green) and CDDP (red) in all cell lines as well 
as the distribution of the mean log IC50 values for 202 drugs in the screen (grey). 
Whiskers extend to whichever is the lower value of the upper/lower quartile +1.5x the 
interquartile range, or the maximum/minimum y value, respectively. Cell lines which 
are less sensitive to 2 are highlighted in a red box. Data for osmium complexes 3 
(FY26) and 4 (FY12) are also shown for comparison. For structures see Figure 1. 
 
 
 
  
FY26 FY12 Mean IC50 ZL49 ZL109 Cisplatin 
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Figure S2. Bar plot of the number of cell lines of each tissue type screened against 
organo-iridium complex 2. Cell lines significantly insensitive to 2 highlighted in green 
with the corresponding % of total cell lines of that type. Tissue groups where no 
percentage is given contained no cell lines resistant to 2. 
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Figure S3. Multidimensional scaling (MDS) plots for RNA sequencing data. (A) 
Samples grouped as control (blue) and 2-exposed (orange), demonstrating a 
differential drug-induced response. (B) Grouping of samples across the time series, 
with 4 h control and 2-exposed samples in blue, 12 h in green, 24 h in orange and 48 
h in red The contrasting behavior of the 48 h datasets compared to earlier time points 
is evident.  
Figure S3 shows natural separation of the samples into clusters, and good 
agreement between the triplicate measurements. The biggest source of 
variation is by time point, the second by exposure-status, i.e. whether they are 
exposed as a control or to a compound.  
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Figure S4. (A) Venn diagram showing the number of differentially-expressed genes 
at 4, 24 and 48 h after exposure to 2. Only those genes with -1.0 < LogFC > 1.0 and 
FDR < 0.05 are included. (B) Graph showing the number of up- (red) and down-
regulated (green) genes at each time point. Only those genes with -1.0 < LogFC > 
1.0 and FDR < 0.05 are included. 
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Figure S5. Generation of reactive oxygen species (ROS) and superoxide (SO) 
analysis by flow cytometry of A2780 ovarian carcinoma cells exposed to complex 2 
for 24 h at IC50 concentration at 310 K.  Cells stained with orange/green fluorescent 
reagents. Pyocyanin was the positive control (orange). 
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Figure S6. Heat map of DEGs In the oxidative stress response pathway in response 
to FY26 (complex 3) published previously.1 Only DEGs with FDR < 0.10 are 
included.  
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Figure S7. Heat map of DEGs for ZL109 (complex 2) in the apoptotic pathway. Only 
DEGs with FDR < 0.10 are included. 
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